IGF1R and acute lymphoblastic leukemia: We provided evidence that the INSR/IGF-1R axis is active in most T-ALL cell lines and that the pharmacological inhibition of IGF-1R sensitizes T-ALL cells to dasatinib treatment, indicating important cross-talks between INSR/IGF-1R and SFKs.